Binding Database

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.

Shionogi

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Bristol Myers Squibb

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

Bristol Myers Squibb

Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.

Qpex Biopharma

Trypsin inhibitors for the treatment of pancreatitis.

Novartis Pharma

Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors.

The University of Queensland

Discovery of novel, potent, isosteviol-based antithrombotic agents.

Peking University

Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3.

The University of Queensland